Señales en vivo de PAB.AX | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (6 may 2024 @ 00:48):

Stats
Volumen de hoy	618 777
Volumen promedio	1.02M
Capitalización de mercado	16.46M
EPS	$0 ( 2024-02-22 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	0
ATR14	$0 (0.00%)

Patrys Ltd Correlación

10 Correlaciones Más Positivas

10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Patrys Ltd Finanzas

Annual	2023
Ingresos:	$2.85M
Beneficio Bruto:	$2.80M (98.35 %)
EPS:	$-0.00340

FY	2023
Ingresos:	$2.85M
Beneficio Bruto:	$2.80M (98.35 %)
EPS:	$-0.00340

FY	2022
Ingresos:	$27 500.00
Beneficio Bruto:	$3.33M (12 122.09 %)
EPS:	$-0.00350

FY	2021
Ingresos:	$27 500.00
Beneficio Bruto:	$27 500.00 (100.00 %)
EPS:	$-0.00377

Financial Reports:

No articles found.

Patrys Ltd

Patrys Limited, together with its subsidiaries, develops and commercializes antibody technologies for the treatment of cancer in Australia. Its lead technology is Deoxymab 3E10, a DNA damage-repair antibody that penetrates cell nuclei. The company also focuses on developing PAT-DX1, an antibody fragment for the treatment of primary and secondary brain cancer. In addition, it is developing PAT-DX3, a full-sized antibody that has DNA-binding and DNA damage repair blocking properties of PAT-DX1 used for tissue distribution, pharmacokinetic profile, etc.; and PAT-DX1-NP, a product based on the targeted delivery of nanoparticles carrying therapeutic payloads to the inside of cancer cells. The company was incorporated in 2006 and is based in Melbourne, Australia.